An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program

Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association

(2022) Joshua J. Joseph et al.   CIRCULATION

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

(2022) Dominik Dahl et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison

(2022) Karan Vadher et al.   DIABETES OBESITY & METABOLISM

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

(2022) Naveed Sattar et al.   NATURE MEDICINE

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

(2022) Tim Heise et al.   Lancet Diabetes & Endocrinology

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Tadej Battelino et al.   Lancet Diabetes & Endocrinology

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Amalia Gastaldelli et al.   Lancet Diabetes & Endocrinology

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

(2022) John P. H. Wilding et al.   Diabetes Therapy

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

(2022) Shweta Urva et al.   CLINICAL PHARMACOKINETICS

WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update

(2022) Lawrence Blonde et al.   Endocrine Practice

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

(2022) Nobuya Inagaki et al.   Lancet Diabetes & Endocrinology

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

(2022) Takashi Kadowaki et al.   Lancet Diabetes & Endocrinology

Twenty-year trends in racial and ethnic enrollment in large diabetes randomized controlled trials

(2022) Jingyi Zhang et al.   BMC Medicine

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

(2022) Michael A. Nauck et al.   Cardiovascular Diabetology

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

(2022) Tamer Coskun et al.   Cell Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2022) Melanie J. Davies et al.   DIABETES CARE

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

(2022) Shweta Urva et al.   LANCET

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

(2022) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

Introduction and Methodology: Standards of Care in Diabetes—2023

(2022) Nuha A. ElSayed et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

(2021) Juan P. Frias et al.   DIABETES CARE

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

(2021) Shweta Urva et al.   CLINICAL PHARMACOKINETICS

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

(2021) Lone B Enebo et al.   LANCET

The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update

(2021) Michael A. Nauck et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

(2021) Julio Rosenstock et al.   LANCET

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

(2021) Bernhard Ludvik et al.   LANCET

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

(2021) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

(2021) Stefano Del Prato et al.   LANCET

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

(2021) Ildiko Lingvay et al.   LANCET

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

(2021) Sean Wharton et al.   POSTGRADUATE MEDICINE

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

(2020) Juan Pablo Frias et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

(2020) Jonathan E. Campbell   Molecular Metabolism

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

(2020) Thinzar Min et al.   Diabetes Therapy

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

(2019) Louis S. Matza et al.   DIABETES OBESITY & METABOLISM

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

(2018) Lawrence Blonde et al.   ADVANCES IN THERAPY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism